Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura
Herein, we report our experience with a novel case of MS concomitant with ITP that was safely treated with ofatumumab. Considering the pharmacological similarities of ofatumumab to rituximab (a second-line treatment for ITP), anti-CD20 monoclonal antibodies such as ofatumumab could be a promising treatment option for cases of MS concomitant with ITP.
Authors
- Yuki Yokota (ORCID: https://orcid.org/0000-0001-9332-5717)
- Hideto Nakajima (ORCID: https://orcid.org/0000-0002-2154-9196)
- Makoto Hara (ORCID: https://orcid.org/0000-0001-8893-6847)
Institutions
- Nihon University (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.3389/fimmu.2025.1515776
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science